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Abstract
The age-associated decline of the neurological and cognitive functions becomes more and more serious challenge for the
developed countries with the increasing number of aged populations. The morphological and biochemical changes in the
aging brain are the subjects of many extended research projects worldwide for a long time. However, the crucial role of
the blood–brain barrier (BBB) impairment and disruption in the pathological processes in age-associated neurodegen-
erative disorders received special attention just for a few years. This article gives an overview on the major elements of
the blood–brain barrier and its supporting mechanisms and also on their alterations during development, physiological
aging process and age-associated neurodegenerative disorders (Alzheimer’s disease, multiple sclerosis, Parkinson’s dis-
ease, pharmacoresistant epilepsy). Besides the morphological alterations of the cellular elements (endothelial cells,
astrocytes, pericytes, microglia, neuronal elements) of the BBB and neurovascular unit, the changes of the barrier at
molecular level (tight junction proteins, adheres junction proteins, membrane transporters, basal lamina, extracellular
matrix) are also summarized. The recognition of new players and initiators of the process of neurodegeneration at the
level of the BBB may offer new avenues for novel therapeutic approaches for the treatment of numerous chronic
neurodegenerative disorders currently without effective medication.
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Structure of the blood–brain barrier
(BBB)
Homeostasis of the extracellular microenvironment in
the neural tissue of the brain as well as its protection
against neurotoxic compounds and variations in the
composition of the blood are important for normal
function of the neurons. It is warranted by a structure
formed between blood and brain, which is therefore
called the BBB.1 Clear evidence for the existence of
this permeability barrier in the brain emerged in 1909
with the demonstration by Edwin Goldman (a South
African-German) that a dye injected into the blood
stream of a rat stained the whole body – except for
the brain and spinal cord. The opposite was also true:
injection of the dye into the cerebral ventricles stained
the brain and spinal cord but not the rest of the body.2,3
This occurs because most organs of the body are per-
fused by capillaries lined with endothelial cells (ECs)
that have small pores (fenestrations) to allow for the
rapid movement of small molecules into the organ
interstitial ﬂuid from the circulation. However, the
capillary endothelium of the brain and spinal cord
lack these pores because the ECs of brain capillary
are connected to each other by continuous tight junc-
tions (TJs), produced by the interaction of several
transmembrane proteins that project into and seal the
paracellular pathway.3–5 The interaction of these junc-
tional proteins eﬀectively blocks the free diﬀusion of
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polar solutes from blood along these potential para-
cellular pathways and so denies access to brain intersti-
tial ﬂuid. Thus, the BBB signiﬁcantly impedes entry
from blood to brain of virtually all molecules, except
those that are small and lipophilic or those that enter
the brain through an active transport mechanism,
particularly with essential nutrients, precursors and
cofactors. The other diﬀerence between the peripheral
and central capillaries is that the brain capillaries are
surrounded by pericytes, basal membrane and astrocyte
end feet, which form a covering layer, that are missing
at the peripheral microvessels. It is well established that
in contrast to leaky vessels in peripheral organs,6 the
BBB restricts entry of polar molecules into the brain,7–9
but can be transported into the brain via speciﬁc trans-
porters expressed in the brain endothelium under
physiological or pathological conditions.10,11
There are ﬁve basic mechanisms by which solute
molecules move across membranes. First is simple dif-
fusion, which proceeds from high to low concentrations
(e.g. sucrose and ethanol). Second is facilitated diﬀu-
sion (glucose via GLUT-1), a form of carrier-mediated
endocytosis, in which solute molecules bind to speciﬁc
membrane protein carriers, also from high to low con-
centration. Third is simple diﬀusion through an aque-
ous channel, formed within the membrane. Fourth is
active transport through a protein carrier (e.g. P-gp and
BCRP) with a speciﬁc binding site that undergoes a
change in aﬃnity. Active transport requires ATP
hydrolysis and conducts movement against the concen-
tration gradient. The ﬁfth is movement between cells is
referred to as paracellular diﬀusion. The BBB has a
number of highly selective mechanisms for transport
of nutrients into the brain.
Several BBB peptide transport mechanisms
(i.e. receptor-mediated, absorptive-mediated, carrier-
mediated and non-speciﬁc passive diﬀusion), as well
as non-transport processes (i.e. endocytosis without
transcytosis, absorption and metabolism) are known.12
The main cellular elements of BBB are (a) the brain
capillary ECs, and these cells are associated with (b)
pericytes that are responsible for the feeding of the
ECs, (c) end feet of the astrocytes covering the
capillaries, and (d) the interacting microglial cells and
(e) neurons (Figure 1). The collective name of these cell
types as a collaborative system in the brain is neurovas-
cular unit (NVU). Beside the cellular elements, BBB
comprises extracellular matrix and basal lamina as the
parts of the protective system. All the cell types have
special structures to ensure the regulation of the pene-
tration of xenobiotics to the brain tissue.
In the ﬁrst part of this review, we will discuss the
barrier function of these cellular elements in interaction
with each other and supporting mechanisms. In the
second part, the alterations of the protective molecular
mechanisms during the process of maturation and
Figure 1. The most important cellular elements of blood–brain barrier (modified from http://www.hcvpi.bham.ac.uk/staff/NF.html).13
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aging will be summarized. In the ﬁnal part, the age-
related neurodegenerative disorders and the role of
BBB disruption in their pathologies will be presented.
Endothelial barrier
Compared with peripheral vasculature, BBB ECs are
characterized by increased mitochondrial content,
exhibit minimal pinocytotic activity, and lack fenes-
trations.14–17. Increased mitochondrial content is
essential for these cells to maintain various active
transport mechanisms such as those utilized to trans-
port ions, nutrients and waste products into and out
of brain parenchyma, thus contributing to precise
regulation of the CNS microenvironment and ensur-
ing proper neuronal function. The high concentration
of mitochondria in cerebrovascular ECs might
account for the sensitivity of the BBB to oxidant
stressors. Furthermore, the physiology and patho-
physiology of ECs are closely linked to the function-
ing of their mitochondria, and mitochondrial
dysfunction is another important mediator of disease
pathology in the brain.18
The brain endothelium is highly reactive because it
serves as both a source of, and a target for, inﬂamma-
tory proteins and reactive oxygen species (ROS).
Neuroinﬂammation and oxidative stress lead to BBB
breakdown, which are implicated in the pathogenesis
of central nervous system (CNS) disease. Cell polarity
of ECs is ascribed to diﬀering functional expression of
transporter proteins and metabolic enzymes that are
diﬀerentially expressed on the luminal (or apical) and
abluminal (or basolateral) membranes, which further
contribute to the high selectivity of the BBB.19–21 Of
the many transporters expressed at the BBB endothe-
lium, several have been implicated in inﬂux and/or
eﬄux of drugs into the CNS. Decreased expression
and/or defective function of transporters, leads to
increased BBB permeability, toxic adverse eﬀects of
drugs and can be an early event in the pathology of
several disorders. Factors that can disrupt the BBB
are varied, ranging from secreted elements to immune
cells and pathogens. Compromised BBB integrity mani-
fests mainly as increased barrier permeability. In add-
ition to direct eﬀects on ECs, other members of the
NVU can be aﬀected, that is pericytes, astrocytes and
basement membrane (BM), which in turn aggravate
impairment of BBB functions. Consequences vary
from dysregulated molecular and ionic ﬂux across the
damaged BBB to the initiation of a central inﬂamma-
tory response. Despite manifold causes, characteristics
and consequences, BBB breakdown generally
culminates in neuronal dysfunction, neuroinﬂamma-
tion and neurodegeneration. Downstream pathological
outcomes and potential for recovery are diverse22
(Figure 2).
Membrane transporters
Eﬄux transporters include P-glycoprotein (P-gp),
Breast Cancer Resistance Protein (BCRP in humans;
Bcrp in rodents) and Multidrug Resistance Proteins
(MRPs in humans; Mrps in rodents) in the brain.
Transporters that facilitate drug entry into the brain
(uptake or inﬂux transporters) include organic anion
transporting polypeptides (OATPs in humans; Oatps
in rodents), organic anion transporters (OATs in
humans; Oats in rodents), organic cation transporters
(OCTs in humans; Octs in rodents), nucleoside trans-
porters, monocarboxylate transporters (MCTs in
humans; Mcts in rodents) and putative transport sys-
tems for peptide transport. The localization of the main
Figure 2. Causes, characteristics and consequences of BBB breakdown (modified from Obermeier et al.22).
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membrane transporter proteins in the apical and baso-
lateral surface of rodent ECs is presented in Figure 3.
The restricted paracellular permeability of capillary
EC layer is warranted by two intercellular molecular
binding systems: the adherens junctions (AJ) and the
TJ (Figure 4).
Adherens junctions
AJs are found throughout the CNS microvasculature
and are responsible for intercellular adherence between
adjacent ECs.15,26 AJs are composed of multiple pro-
tein components including vascular endothelium (VE)
cadherin, actinin and catenin.21 Cell–cell adhesion is
Figure 3. Localization of membrane transporters in the endothelial cells23,24 at the BBB in rodents (modified from the website of
Solvo Biotechnology25).
Figure 4. Tight and adherens junctions components. Tight junctions (TJs) are the most apical intercellular junctions in ECs. Their
major transmembrane components are the claudins, occludin and adhesion molecules (JAMs), whereas their cytoplasmic components
are zonula occludens (ZOs) proteins. Adherens junctions (AJs) are localized just below TJs; their transmembrane components are
cadherins and nectins that complex respectively the cytoplasmic components b-catenin and afadin.
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mediated by homophilic interactions of VE-cadherin
expressed on adjacent ECs. Such interactions mediate
calcium-dependent cell adhesion by binding to the actin
cytoskeleton. Cytoskeletal binding occurs via catenin
accessory proteins. Speciﬁcally, b-catenin links VE-cad-
herin to a-catenin, an interaction that induces the direct
binding to actin.14,20
Tight junctions
Although disruption of AJs can result in increased
BBB permeability, TJs are primarily responsible for
restricting paracellular permeability at the BBB.26,27
TJs form the primary physical barrier component of
the BBB and function to greatly restrict paracellular
entry of various endogenous and exogenous sub-
stances that can potentially be neurotoxic. Such TJs
impart a high trans-endothelial electrical resistance
(TEER) across the BBB (1500–2000  cm2) that
restricts free ﬂow of ions and solutes.28 TJs are
dynamic complexes of multiple protein constituents
including junctional adhesion molecules (JAMs),
occludin, claudins (i.e. claudin-1, -3 and -5) and
membrane-associated guanylate kinase (MAGUK)-
like proteins (i.e. ZO-1, -2 and -3).26
Basal membrane
BMs (it is also called as basal lamina) are considered to
be uniform, thin extracellular matrix sheets that serve
as a substrate for ECs. To ﬁnd out whether BMs main-
tain their ultrastructure, protein composition and bio-
physical properties throughout life the natural aging
history of the human inner limiting membranes (ILM)
was investigated by Candiello et al.29 Transmission
electron microscopy showed that the ILM steadily
increases in thickness from 70 nm at foetal stages to
several microns at age 90. Furthermore, the relative
concentrations of collagen IV and argin increase, and
the concentration of laminin decreases with age. Force-
indentation measurements by atomic force microscopy
also showed that ILMs become increasingly stiﬀer with
advancing age.29
Extracellular matrix
The extracellular matrix of the basal lamina serves as
an anchor for the cerebral microvascular endothelium.
The anchoring function of the extracellular matrix is
mediated via interactions between endothelial integrin
receptors, lamin and other matrix proteins. Disruption
of extracellular matrix is associated with loss of barrier
function, resulting in increased permeability.
Additionally, matrix proteins have been shown to inﬂu-
ence the expression of TJ proteins, such as occludin,
suggesting that the extracellular matrix plays a role in
maintaining TJ protein integrity.15,26,30
Astrocytes
Astrocytes are the most abundant cell type in the brain
and display a ﬁbroblast-like morphology within grey
matter15,31; however, this morphology can be inﬂu-
enced by their CNS location and associations with
other cell types that are in close proximity.32
Astrocyte end-feet cover over 99% of cerebral capil-
laries,33 leading to critical cell–cell interactions that dir-
ectly modulate and regulate BBB characteristics.32
Several studies have demonstrated that astrocytes
play a vital role in maintenance, and perhaps induction,
of BBB characteristics.
Astrocytes are fundamental for homeostasis, defence
and regeneration of the CNS. Loss of astroglial func-
tion and astroglial reactivity contributes to the aging of
the brain and to neurodegenerative diseases. Changes
in astroglia in aging and neurodegeneration are highly
heterogeneous and region-speciﬁc.34
Several inducing factors secreted by astrocytes have
been identiﬁed, including TGF-b, GDNF and BFGF,
which are involved in induction and regulation of the
BBB phenotype. Additionally, astrocytes can regulate
brain microvascular permeability via Ca2þ signalling
involving astrocyte-endothelial gap junctions and pur-
inergic transmission.15,26,30,32 Astrocytes play a critical
role in preventing excitotoxicity induced by acute ele-
vations of glutamate in the brain. This is mediated via
expression of astrocyte glutamate transporters excita-
tory amino acid transporters (EAAT1 and EAAT2)
that are responsible for glutamate uptake into the
astrocyte cell, thus reducing glutamate levels in the
parenchyma.35
Lipoproteins in plasma transport lipids between tis-
sues, however, only high-density lipoproteins (HDL)
appear to traverse the BBB; thus, lipoproteins found
in the brain must be produced within the CNS.
Apolipoproteins E (ApoE) and ApoJ are the most
abundant apolipoproteins in the brain, which are
mostly synthesized by astrocytes.36 ApoE has an
important role in the pathology and BBB injury
during the development of Alzheimer’s disease (see
more details later in this article).
There is also evidence that astrocytes progressively
accumulate in the normal aging brain, increasing in
both number and size. These astrocyte changes in
normal brain aging may, in the event of an injury, con-
tribute to the exacerbated injury response and poorer
outcomes observed in older traumatic brain injury sur-
vivors.37 Astrocyte morphology changes and GFAP
expression increases progressively during aging in
humans and rodents.38,39
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Pericytes
Pericytes are BBB associated cells. During aging, peri-
cytes show ultrastructural changes such as vesicular
and lipofuscin-like inclusions1,40–43; an increased size
of mitochondria44 and a foamy transformation.45
Ueno et al.46 reported on membranous inclusions
within the basal lamina or the ECM of the microvessels
and suggested the degeneration of pericytes. de Jong
et al.47 in the aging rat and Stewart et al.48 in the
aging human brain showed the degeneration and loss
of pericytes. Burns et al.49,50 described the reduction of
the cross-sectional area of pericytes in aging monkey
and rat brain. However, Peters et al.42 found no
change in the number of pericytes in monkey, and
Heinsen and Heinsen51 and Peinado et al.41 showed
an increase in the number of pericytes in the rat
aging brain. The obvious discrepancies in the literature
could be explained by considering the degeneration and
the proliferation of pericytes as distinct age-related
mechanisms. Accordingly, Scheibel and Fried52 could
show that pericytes in aging brain begin to lose their
contact to the EC and begin to migrate. This behaviour
seems to be a response of the pericytes to a yet uniden-
tiﬁed age-related eﬀect. The PDGF released by ECs is
known to bind to the PDGF receptor expressed by
pericytes and to attract pericytes to ECs.53,54 If this
ligand-receptor system is disturbed, the functional
integrity of the vessel is impaired.53,55 With age, this
system could deteriorate as well, but data are not avail-
able as yet.
Montagne and coworkers showed that pericyte
injury and possibly early degeneration correlates with
increased BBB permeability within the hippocampus,56
a region known to be aﬀected by pericyte loss and BBB
breakdown on post-mortem tissue analysis in
Alzheimers’ disease.57
Microglia
Microglia, the primary immune cells of the brain, are
ubiquitously distributed in the CNS and are activated
in response to systemic inﬂammation, trauma and sev-
eral CNS pathophysiologies.15,58–60 This cell type is not
the basic element of the BBB, but it has an impact on
the BBB function and integrity. Microglia present with
a ramiﬁed morphology that is characterized by a small
soma and ﬁne cellular processes during their ‘‘resting
state’’. Microglial activation in response to patho-
physiological stressors can trigger changes cell morph-
ology, which include reduced complexity of cellular
processes and transition from a ramiﬁed morphology
to an amoeboid appearance.59 Activated microglia pro-
duces high levels of neurotoxic and proinﬂammatory
mediators such as nitric oxide, peroxide, TNF-a and
proteases, all of which result in cell injury and neuronal
death,30 As immune cells microglia scavenge apoptotic
cells, tissue debris after trauma, or microbes.30 They
can also act as scavengers of extracellular molecules
such as amyloid-b.59,60 Activation of microglia is asso-
ciated with altered TJ protein expression and increased
BBB permeability.61
Brieﬂy the major physiological protective eﬀector
functions of microglia: (a) Proliferation, (b) morpho-
logical transformation, (c) motility and migration,
(d) intercellular communication, (e) phagocytosis and
(f) proteostasis. With aging, microglia shift their
morphology and may display diminished capacity for
normal functions related to migration, clearance and
the ability to shift from a proinﬂammatory to an anti-
inﬂammatory state to regulate injury and repair.62
Neurons
There is considerable evidence for direct innervation
of both brain microvessel ECs and associated
astrocyte processes via distinct connections with
noradrenergic,15,62,63 serotonergic,64 cholinergic65,66
and GABAergic67 neurons. Therefore, neurons are in
connection with the BBB and have inﬂuence on the
behaviour of capillary endothelial barrier. For example,
studies have shown that loss of direct noradrenergic
input from the locus coeruleus results in increased
BBB susceptibility to eﬀects of acute hypertension,
resulting in signiﬁcantly increased permeability to
125-I labelled albumin.68
With aging, cell senescence can contribute to BBB
compromise. The compromised BBB allows an inﬂux of
inﬂammatory cytokines to enter the brain. These cyto-
kines lead to neuronal and glial damage. Several factors
contribute to the deterioration of synaptic plasticity
with age and one of these factors appears to be a heigh-
tened level of activation of microglia, which may reﬂect
impairment in the homeostatic ability of these cells with
age, or an increase in responsiveness to modulatory
molecules. The age-related decrease in tissue perfusion,
together with the increase in BBB permeability may
alter the microenvironment in the brain; this, combined
with the proposed age-related compromised homeo-
static capability of microglia, may be a signiﬁcant
factor in maintaining the neuroinﬂammatory changes,
which have been described in the aged brain and which
exert a negative impact on synaptic function. These
combined changes may contribute to the deﬁcit in
long-term potentiation (LTP) in perforant path-granule
cell synapses of aged animals.69 Ultimately, the
functional neuronal changes within the brain can
cause age-related disease.
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Changes in the BBB with
physiological aging
How to deﬁne physiological aging? It is evident even
from casual observation of physical activities, such as
walking, that elderly people exhibit a deterioration of
physiological processes. Moreover, the inability of ath-
letes to continue peak performance when they reach
their 30s or 40s indicates that deterioration begins at
a relatively young age and progresses in severity from
that point on. Indeed, many studies have conﬁrmed that
most physiological processes deteriorate progressively
after about 30 years of age, some functions more severely
aﬀected than others. Diseases that do not occur until, or
increase in frequency at, advanced ages are called age-
associated diseases. Coronary heart disease, stroke,
many types of cancer, osteoporosis, Alzheimer’s disease,
Parkinson’s disease (PD) and other neurodegenerative
disorders are examples of such diseases commonly
found in elderly people. Indeed, age-associated disease
underlies much of the physiological deterioration of old
age. However, many studies focus on subjects who are
free of discernible disease in what they refer to as the
study of ‘normal aging or physiological aging’ (Edward
J Masoro, Medicine Encyclopedia, Aging Healthy).
Concerning aging of the brain and BBB, physiological
aging can be deﬁned as a deterioration of the functions
without cognitive decline and dementia.
Dysfunction of BBB appears and it is associated
with inﬂammation and loss of TJs without leukocyte
recruitment at adult period and aging. Cell damage is
characterized by nuclear DNA damage and can con-
tribute to aging either indirectly by increasing apoptosis
or cellular senescence or directly by increasing cell
dysfunction.
The matured immune system is also entering into
function to regulate the passage of cells and molecules
from the periphery to the CNS through BBB. For
example, ECs selectively regulate trans-endothelial
migration of T-helper lymphocytes (Th1 and Th2) sup-
pressing the initiation of CNS autoimmune.70 TJ bar-
riers of ECs prevent the free entry of blood-derived
substances; thereby maintain the extracellular environ-
ment of the brain. Astrocytes express TJ proteins and
densely and tightly surround mature neurons to protect
them from blood-derived neurotoxic substances.71
The main changes at the BBB during physiological
aging are presented in Table 1.
Changes at the BBB associated with age-
related neurodegenerative pathologies
An important component of age-related pathology is
neurodegeneration. It can be deﬁned as progressive
loss of neuronal structure and function, ﬁnally leading
to neuronal cell death. Most neurodegenerative diseases
have their onset in mid-life and can be characterized by
motor and/or cognitive symptoms that progressively
worsen with age and may reduce life expectancy.
Neurodegenerative diseases and changes in BBB
functionality
In neurodegeneration, changes in functionality of the
BBB and supporting cells (NVU) lead to BBB
dysfunction in a more progressed state of the disease
process27,32,78–81 (Figure 2). Previously, Zhao et al.
reviewed the establishment and dysfunction of the
BBB, with associations between BBB breakdown and
pathogenesis of inherited monogenic neurological dis-
orders and complex multifactorial diseases, including
Alzheimer’s disease.82 Moreover, brain vascular
damage can cause BBB dysfunction and/or reduced
brain blood perfusion and hypoxia. These processes
lead to neuronal injury and neurodegeneration.
Below changes in BBB functioning in Alzheimer’s
disease, multiple sclerosis, PD and pharmacoresistant
epilepsies are presented in a more disease speciﬁc
manner.
BBB in Alzheimer’s disease
Alteration of the BBB plays an important role in
Alzheimer’s disease.79,83,84 While BBB breakdown is
an early event in the aging human brain that begins
in the hippocampus and may contribute to cognitive
impairment.56 With mild cognitive impairment, the
BBB breakdown in the hippocampus worsens and is
correlated with injury to BBB-associated pericytes, as
shown by cerebrospinal ﬂuid (CSF) analysis.56 Cellular
and molecular mechanisms in cerebral blood vessels
and the pathophysiological events that lead to cerebral
blood ﬂow dysregulation and disruption of the NVU
and the BBB may contribute to the onset and progres-
sion of dementia and Alzheimer’s disease. Also, there is
a link between neurovascular dysfunction and neurode-
generation (including the eﬀects of Alzheimer’s disease
genetic risk factors on cerebrovascular functions and
clearance of amyloid-b (Ab)), and the impact of vascu-
lar risk factors, environment and lifestyle on cerebral
blood vessels, which in turn may aﬀect synaptic, neur-
onal and cognitive functions, as reviewed by Nelson
et al.85
Tight junctions. Both the components and functioning of
TJs proteins are aﬀected by neurodegenerative pro-
cesses.79 TJ proteins include occludin and claudins
(for example, claudin-3, -5 and -12). Occludin is
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vulnerable to be attacked by matrix metalloproteinases
(MMPs) and MMPs seem to have implications in
Alzheimer’s disease.86,87 Furthermore, connection of
adherens and TJs to the actin cytoskeleton is inﬂuenced
by tau and may result in tau-induced neurotoxicity.88
Without knowing the exact mechanisms, TJs seem to
be involved in receptor for advanced glycation end-pro-
ducts (RAGE)-mediated Ab cytotoxicity to the brain
microvascular ECs, resulting in damaged BBB struc-
tural integrity. RAGE is a multiligand membrane
receptor and is the main factor mediating Ab cytotox-
icity in AD. It has interaction with Ab stimulating acti-
vation of proinﬂammatory cytokines, release of ROS,
which leads to neuron damage and BBB dysfunction.89
Astrocytes. Astrocytes normally regulate BBB function-
ality, and abnormal astrocytic activity coupled to vas-
cular instability has been observed in Alzheimer’s
disease models.90 It seems that astrocyte properties
are aﬀected upon development of amyloid deposits.79,91
Pericytes. Loss of pericytes may damage the BBB due to
an associated decrease in cerebral capillary perfusion,
blood ﬂow and blood ﬂow responses to brain activa-
tion. This will lead to more chronic perfusion problems
like hypoxia, while BBB breakdown may further lead to
brain accumulation of blood proteins and several
macromolecules with toxic eﬀects on the vasculature
and brain parenchyma, ultimately leading to secondary
neuronal degeneration.79,92
Pericytes are uniquely positioned within the NVU
between ECs of brain capillaries, astrocytes and neu-
rons. Winkler et al. have reviewed the concept of the
NVU and neurovascular functions of CNS pericytes,
discussing vascular contributions to Alzheimer’s disease
and new roles of pericytes in the pathogenesis of
Table 1. Alterations of BBB constituents during physiological aging.
BBB elements Properties References
ECs Capillary wall thickness:
increased in humans
decreased in rats
decreased in monkeys
Number of ECs:
decreased in humans
Number of mitochondria:
decreased
Hunziker et al.72
Hicks et al.44
Burns et al.49
Hunziker et al.72
Burns et al.49,50
Grammas et al.18
Tight junctions Expression of tight junction proteins:
decreased
Elahy et al.,71 Enciu et al.73
Basal lamina Thickness of basement membrane:
Increased
Concentration of collagen IV and argin:
Increased
Concentration of laminin:
decreased
Candiello et al.,29 Ravens74
Candiello et al.29
Candiello et al.29
Astrocytes Astrocyte proliferation:
Increased number and size
GFAP expression:
Increased
Rodriguez-Arellano et al.,34
Harris et al.37
Chisholm and Sohrabji,38
Middeldorp and Hol39
Microglia Changes to amoeboid morphology
Production of neurotoxic proinflammatory mediators
Kettenmann et al.59
Ronaldson and Davis30
Pericytes Number of pericytes:
Degeneration and loss of pericytes
Ultrastructural changes:
vesicular and lipofuscin-like inclusions,
increased size of mitochondria,
foamy transformation
Stewart et al.,48 Burns et al.49,50
Rascher and Wolburg1
Hicks et al.44
Sturrock45
Neurons Deterioration of synaptic plasticity
Deficit in long-term potentiation
Impaired neurogenesis
Increased apoptosis
Neuronal damage due cytokine release
Blau et al.69
Blau et al.69
Lucke-Wold et al.75
Lucke-Wold et al.,75 Cerbai et al.76
Buschini et al.77
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Alzheimer’s disease such as vascular-mediated Ab-inde-
pendent neurodegeneration, regulation of Ab clearance
and contributions to tau pathology, neuronal loss and
cognitive decline.93 Pericytes demonstrate large num-
bers of intracellular inclusions, pinocytotic vesicles,
large lipid granules and mitochondrial abnormalities
suggesting cellular dysfunction and/or degener-
ation.94,95 Also, pericyte degenerative changes are asso-
ciated with capillary reductions and gross dilatation
and tortuosity of surviving vessels.95 In post-mortem
tissue of individual AD subjects, reductions in pericyte
coverage inversely correlate with evidence of BBB dis-
ruption, such as leakage of the plasma proteins includ-
ing immunoglobulin G and ﬁbrin.57 This indicates that
pericyte dysfunction and/or loss are associated with key
attributes of AD vascular pathology – vascular regres-
sion and disrupted vascular permeability.93
Furthermore, APOEX genetic background and peri-
cyte degeneration seem to be related. Halliday et al.96
have shown that accelerated pericyte degeneration in
Alzheimer’s disease APOE4 carriers>AD APOE3 car-
riers> non-Alzheimer’s disease controls, correlates
with the magnitude of BBB breakdown to immuno-
globulin G and ﬁbrin. Also, accumulation of the proin-
ﬂammatory cytokine CypA and of MMP-9 in pericytes
and ECs in Alzheimer’s disease (APOE4>APOE3) has
been shown to lead to BBB breakdown in transgenic
APOE4 mice. This indicates that APOE4 leads to accel-
erated pericyte loss and enhanced activation of LRP1-
dependent CypA–MMP-9 BBB-degrading pathway in
pericytes and ECs, which can mediate a greater BBB
damage in AD APOE4 compared with Alzheimer’s dis-
ease APOE3 carriers.96
Pericytes also have a role in brain cholesterol
homeostasis as they express the cholesterol eﬄux regu-
latory protein (CERP), also known as ABCA1, which
mediates the eﬄux of cholesterol and phospholipids to
lipid-poor apolipoproteins (apo-A1 and apoE), as well
as the nuclear liver X receptors (LXRs). In the brain,
excess cholesterol is metabolized into 24S-hydroxycho-
lesterol (24S-OH-chol), which is an endogenous ligand
for LXR.97
Shimizu et al. demonstrated that the GDNF,
secreted from the brain and peripheral nerve pericytes,
is one of the key molecules responsible for the up-reg-
ulation of claudin-5 expression and the permeability in
the BBB.98
Furthermore, pericytes are able to internalize the
amyloid-b peptides, which accumulate in brain of
Alzheimer’s disease patients.97 With amyloid deposits
detected within degenerating pericytes in the brains of
patients with Alzheimer’s disease, it seems that pericyte
dysfunction may also play a role in cerebral hypoperfu-
sion and impaired amyloid b-peptide clearance in
Alzheimer’s disease.99
Transport and elimination of amyloid- (A) at the
BBB. Active transport of Ab across the BBB seems to
occur by a number of transporters seems to occur by a
number of transporters that control the level of the
soluble isoform of Ab in brain.
P-glycoprotein. P-glycoprotein (P-gp, MDR1,
ABCB1) contributes to the eﬄux of brain-derived Ab
into blood.92,100–105 It seems that, in addition to the
age-related decrease of P-gp expression, Ab1-42 itself
downregulates the expression of P-gp and other Ab-
transporters, which could exacerbate the intracerebral
accumulation of Ab and thereby accelerate neurode-
generation in Alzheimer’s disease and cerebral b-amy-
loid angiopathy (Figure 5). Defects in P-gp-mediated
Ab clearance from the brain are thought to be triggered
by systemic inﬂammation by lipopolysaccharide, lead-
ing to increased brain accumulation of Ab.106 Recently,
reduction of P-gp expression and transport activity has
been found in isolated capillaries, as a result of Ab40
mediated P-gp ubiquitination, internalization and pro-
teasome-dependent degradation.107
Low-density lipoprotein receptor-related protein 1
(LRP1). Ab is produced from the amyloid-b precursor
protein (APP), both in the brain and in peripheral tis-
sues. In plasma, a soluble form of LRP1 (sLRP1) is the
major transport protein for peripheral Ab. sLRP1
maintains a plasma ‘sink’ activity for Ab through bind-
ing of peripheral amyloid-b, which in turn inhibits reen-
try of free plasma amyloid-b into the brain. LRP1 in
the liver mediates systemic clearance of amyloid-b.
LRP1 at the BBB contributes to the clearance of amy-
loid-b from the brain. LRP1 mediates rapid eﬄux of a
free, unbound form of amyloid-b and of amyloid-b
bound to apolipoprotein E2 (APOE2), APOE3 or a2-
macroglobulin from the brain’s interstitial ﬂuid into the
blood, and APOE4 inhibits such transport.108 In
Alzheimer’s disease, LRP1 expression at the BBB is
reduced and amyloid-b binding to circulating sLRP1
is compromised by oxidation.103 Moreover, amyloid-b
damages its own LRP1 mediated transport by oxidat-
ing LRP1.109 Defects in LRP-1-mediated Ab clearance
from the brain are thought to be triggered by systemic
inﬂammation by lipopolysaccharide, leading to
increased brain accumulation of amyloid-b.110,111
Low-density lipoprotein receptor-related protein 2
(LRP2). LRP2 mediated transcytosis112 eliminates amy-
loid-b that is bound to clusterin (also known as apoli-
poprotein J) by transport across the BBB, and shows a
preference for the 42-amino-acid form of this peptide.
RAGE. RAGE provides the key mechanism for
inﬂux of peripheral amyloid-b into the brain across
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the BBB either as a free, unbound plasma-derived pep-
tide and/or by amyloid-b-laden monocytes. Faulty vas-
cular clearance of amyloid-b from the brain and/or an
increased re-entry of peripheral amyloid-b across the
blood vessels into the brain can elevate amyloid-b
levels in the brain parenchyma and around cerebral
blood vessels. At pathophysiological concentrations,
amyloid-b forms neurotoxic oligomers and also self-
aggregates, which leads to the development of cerebral
b-amyloidosis and cerebral amyloid angiopathy.79
More insight into the molecular mechanisms underly-
ing amyloid-b-RAGE interaction-induced alterations
in the BBB have been provided by Kook et al.113
They found that Ab1-42 induces enhanced permeabil-
ity, disruption of zonula occludin-1 (ZO-1) expression
in the plasma membrane and increased intracellular cal-
cium and MMP secretion in cultured ECs in vitro, and
disrupted microvessels near amyloid-b plaque-depos-
ited areas, elevated RAGE expression and enhanced
MMP secretion in microvessels of the brains of
5XFAD mice, an animal model for Alzheimer’s disease.
The BBB transport mechanisms for amyloid-b are dis-
played in Figure 5.
Amyloid-b-degrading enzymes. Cerebral ECs, peri-
cytes, vascular smooth muscle cells, astrocytes, micro-
glia and neurons express diﬀerent amyloid-b-degrading
enzymes, including neprilysin, insulin-degrading
enzyme, tissue plasminogen activator and MMPs,
which contribute to amyloid-b clearance. In the circu-
lation, amyloid-b is bound mainly to soluble LRP1
(sLRP1), which normally prevents its entry into the
brain. Systemic clearance of amyloid-b is mediated by
its removal by the liver and kidneys.
Other transporters at the BBB
Glutamate transporters. It has been suggested that
glutamate excitotoxicity plays a role in the neurodegen-
erative processes in Alzheimer’s disease.114 Strict con-
trol L-glutamate concentration in the brain
extracellular ﬂuid is important to maintain neurotrans-
mission and avoid excitotoxicity. The role of astrocytes
in handling L-glutamate transport and metabolism is
well known; Na (þ)-dependent transporters for glutam-
ate exist on astrocytes (EAAT1 and EAAT2) and
neurons (EAAT3). These transporters presumably
Figure 5. The role of blood–brain barrier transport in brain homeostasis of amyloid-b. Neurovascular pathways to neurodegen-
eration in Alzheimer’s disease and other disorders.79
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assist in keeping the glutamate concentration low in the
extracellular ﬂuid of brain. Glutamate transporters
(EAAT1, EAAT2 and EAAT3) at the BBB determine
the levels of brain extracellular glutamate and are
essential to prevent excitotoxicity,114 prompting the
question whether changes in these transporters may
contribute to glutamate excess and excitotoxicity.
High aﬃnity concentrative uptake of L-glutamate
occurs from the brain extracellular ﬂuid into the capil-
lary ECs. The mechanisms in between L-glutamate
uptake in the ECs and L-glutamate appearing in the
blood may involve a luminal transporter for L-gluta-
mate, metabolism of L-glutamate and transport of
metabolites or a combination of the two.115
Furthermore, Na(þ)-dependent glutamate transport
was described on the abluminal membrane of the
BBB116 that help in lowering brain extracellular glu-
tamate concentrations.117 The Naþ-dependent cotran-
sporters of the abluminal membrane are in a position to
actively transport amino acids from the extracellular
ﬂuid into the ECs of the BBB. These active transporters
couple with the energy of the Naþ-gradient to move
glutamate and glutamine into ECs, whereupon glutam-
ate can exit to the blood on the luminal facilitative glu-
tamate transporter. Glutamine may also exit the brain
via separate facilitative transport system that exists on
the luminal membranes, or glutamine can be hydro-
lysed to glutamate within the BBB, thereby releasing
ammonia that is freely diﬀusible. The g-glutamyl cycle
participates indirectly by producing oxoproline (pyro-
glutamate), which stimulates almost all secondary
active transporters yet discovered in the abluminal
membranes of the BBB.
Glucose transporters. Also facilitative glucose trans-
port in the brain is aﬀected in diﬀerent pathophysio-
logical conditions including Alzheimer’s disease.118
Protein expression of the glucose transporter GLUT1
is reduced in brain capillaries in Alzheimer’s disease,
without changes in GLUT1 mRNA structure119 or
levels of GLUT1 mRNA transcripts.120 Furthermore,
a reduction in CNS energy metabolites has been seen in
several Positron Emission Tomography (PET) scanning
studies of Alzheimer’s patients using ﬂuoro-deoxy-glu-
cose (FDG),121–123 likely because the surface area at the
BBB available for glucose transport is substantially
reduced in Alzheimer’s disease.120,124
Furthermore, GLUT1 deﬁciency in mice overexpres-
sing amyloid b-peptide precursor protein leads to early
cerebral microvascular degeneration, blood ﬂow reduc-
tions and dysregulation and BBB breakdown, and to
accelerated amyloid b-peptide pathology, reduced
amyloid b clearance, diminished neuronal activity,
behavioural deﬁcits and progressive neuronal loss and
neurodegeneration that develop after initial
cerebrovascular degenerative changes. Moreover,
GLUT1 deﬁciency in endothelium, but not in
astrocytes, initiates the vascular phenotype as shown
by BBB breakdown. This indicates that reduced BBB
GLUT1 expression worsens Alzheimer’s disease
cerebrovascular degeneration, neuropathology and
cognitive function.125
Possible relationships between BBB dysfunction
(measured by serum/CSF albumin index (Qalb) and
IgG index) with glucose consumption as indicated by
F-FDG PET studies in a selected population with by
Alzheimer disease, indicated a signiﬁcant negative cor-
relation between the increase of serum/CSF albumin
index and F-FDG uptake in the left superior temporal
gyrus, with higher values of Qalb being related to a
reduced glucose consumption in these areas. But, no
signiﬁcant relationships have been found between
brain glucose consumption and IgG index. This suggest
that BBB dysfunction is related to reduction of cortical
activity in the left temporal cortex in AD subjects.126
Miscellaneous
MMP-2 and MMP-9. MMPs are a family of enzymes
able to degrade components of the extracellular matrix,
which is important for normal BBB function. MMP-2
and MMP-9 have been implicated in the physiological
catabolism of Alzheimer’s amyloid-b. Conversely, their
association with vascular amyloid deposits, BBB
disruption and haemorrhagic transformations after
ischemic stroke also highlights their involvement in
pathological processes.127 MMP function is regulated
by tissue inhibitors of matrix metalloproteinases
(TIMPs). Speciﬁcally, the metalloproteinases MMP-2
and MMP9 have been associated in BBB breakdown
in neurodegenerative diseases, including Alzheimer’s
disease.128,129 Chemokines in the brain can recruit
immune cells from the blood or from within the
brain130 to secrete MMP-2 and MMP-9 that increase
BBB permeability.131 Inhibition of this process is linked
to more rapid disease progression.132 Their increasing
prevalence with an increasing number of risk factors
(hypertension, hyperlipidemia, diabetes, male sex and
advanced age)133,134 and lower levels of TIMPs in
Alzheimer’s disease patients with microbleeds suggest
less MMP inhibition in patients with concurrent cere-
bral microbleeds.128
APOE4 homozygosity. While it is well appreciated
that APOE4 homozygosity is associated with an
increased risk of sporadic Alzheimer’s disease, its eﬀects
on the brain microvasculature and BBB have been less
appreciated. Interestingly, APOE (4,4) is associated
with thinning of the microvascular First easement
membrane in Alzheimer’s disease.94
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First evidence that chronic intake of a high-fat diet
induces a dramatic extravasation of immunoglobu-
lins, indicating alterations in BBB functioning, in
the brains of apoE-knockout mice, but not of
C57Bl/6 control mice was provided by Mulder
et al.135 Detoriation of the BBB was shown by IgG
extravasation as well as for BBB transport of a small
hydrophilic marker for BBB permeability (ﬂuores-
cein). For apoE3-Leidenmice that were kept on a
high-fat, high-cholesterol diet and that developed
atherosclerosis to an extent similar to the apoE-
knockoutmice, no signs of BBB disturbances were
found, indicating the importance of ApoE type in
the maintenance of the integrity of the BBB.
A recent study by Bell et al.94 suggested that CypA is
a key target for treating APOE4-mediated neurovascu-
lar injury and the resulting neuronal dysfunction and
degeneration; indeed, activating a proinﬂammatory
CypA-nuclear factor-jB-MMP-9 pathway in pericytes
is associated with increased susceptibility of the BBB to
injury in APOE4 conditions.82
Cerebral microbleeds. Cerebral microbleeds as con-
sequences of BBB breakdown in Alzheimer’s disease
are thought to represent cerebral amyloid angiopathy.
Cerebral microbleeds are seen as possible predictors of
intracerebral haemorrhage. It was found that the inci-
dence of brain microbleeds positively correlates with
age.133,134
BBB in multiple sclerosis
Formation of multiple sclerosis focal lesions follows
extravasation of activated leukocytes from blood
through the BBB into the CNS. Once the activated
leukocytes enter the CNS environment, they propagate
massive destruction to ﬁnally result in the loss of both
myelin/oligodendrocyte complex and neurodegenera-
tion. Also, the activated leukocytes locally release
inﬂammatory cytokines and chemokines leading to
focal immune activation of the brain ECs, and loss of
the normal functioning of the BBB.136,137 While periph-
eral blood leukocyte inﬁltration plays an essential role
in lesion development, there is also evidence suggesting
that BBB dysfunction precedes immune cell inﬁltration.
Recent evidence suggest that immune-mediated activa-
tion (or damage) of the various BBB cellular compo-
nents signiﬁcantly contributes to lesion development
and progression.138,139 Chemokines seem to play an
important role in the cascade of leukocyte extravasa-
tion. Chemokines displayed along the endothelial
lumen bind chemokine receptors on circulating leuko-
cytes, initiating intracellular signalling that culminates
in integrin activation, leukocyte arrest and
extravasation.140
TJs. Increased permeability of the BBB is associated
with decreased expression of TJ and AJ proteins in
the brain capillary ECs. Dephosphorylation of occludin
in a multiple sclerosis mouse model precedes visible
signs of disease, before changes in the BBB permeabil-
ity were observed.141 Tight junctional abnormalities are
most common in active lesions, but are present in inac-
tive lesions in normal-appearing white matter. Tight
junctional abnormalities are positively associated with
leakage of the serum protein ﬁbrinogen, which has
recently been shown to be an activator of
microglia.139,142
MMPs. Also multiple sclerosis MMPs seem to have
implications,86,87 as increased activity of MMPs may
attack the TJ protein occludin. An increase in MMP-
9 activity has been demonstrated at sites of BBB dis-
ruption showing leukocyte inﬁltration. Moreover, the
timing of MMP activity in pial and parenchymal vessels
correlated with the timing of increased BBB
permeability.142
Active transporters
P-glycoprotein (p-gp), multidrug resistance related pro-
tein-1 (MRP1), breast cancer resistance protein
(BCRP). P-gp functionality seems to be impaired in
neuroinﬂammation and may play a role in immunomo-
dulation.143,144 P-gp expression and function are
strongly decreased during neuroinﬂammation. In
vivo, the expression and function of brain endothelial
P-gp in experimental allergic encephalomyelitis (EAE),
an animal model for multiple sclerosis, were signiﬁ-
cantly impaired. Strikingly, vascular P-gp expression
was decreased in both multiple sclerosis and EAE
lesions and its disappearance coincided with the pres-
ence of perivascular inﬁltrates consisting of
lymphocytes.143
Cerebrovascular expression of P-glycoprotein was
decreased in both active and chronic inactive multiple
sclerosis lesions. Moreover, foamy macrophages in
active multiple sclerosis lesions showed enhanced
expression of MRP-1 and BCRP.145 Also, CD8(þ) T
lymphocyte traﬃcking into the brain is dependent on
the activity of P-gp146 (Figure 6).
Transendothelial migration of immune cells. Following
exposure of genetically susceptible individual to as yet
unknown environmental factor(s), leukocytes are acti-
vated against CNS antigens. Activated leukocytes,
mainly CD4T lymphocytes and macrophages set in
motion cerebral endothelial activation and injury by
releasing proinﬂammatory cytokines (e.g. IFN-g and
TNF-a) and chemokines. Expression of endothelial
cell adhesion molecules (ECAMs) such as VCAM-1,
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ICAM-1, MAdCAM-1, E-selectin and PECAM-1 by
activated cerebral ECs is upregulated. Some ECAMs
are shed as vesicles from endothelial membranes carry-
ing ECAMs from the parent EC known as ‘endothelial
microparticles’ (EMP). The molecular organization of
the TJs/AJs of the BBB is also possibly altered by
eﬀects of proinﬂammatory cytokines (particularly
IFN-g) on expression of occludin and other tight junc-
tional elements. Activated leukocytes also secrete
MMPs, which may promote transendothelial migration
of these cells into the CNS by degrading extracellular
matrix macromolecules. Binding of putative multiple
sclerosis antigen(s) within the CNS to CD4T lympho-
cyte receptor and MHC (trimolecular complex) further
promotes the inﬂammatory cascade against bound
antigen(s).
MicroRNAs (miRNAs). While the complex network of
molecular players that leads to BBB dysfunction in
multiple sclerosis is yet to be fully elucidated, recent
studies indicated a critical role for miRNAs in control-
ling the function of the barrier endothelium in the
brain.148 Emerging evidence that indicates that brain
endothelial miRNAs regulate barrier function and
orchestrate various phases of the neuroinﬂammatory
response, including endothelial activation in response
to cytokines as well as restoration of inﬂamed endothe-
lium into a quiescent state.108
Figure 6. Possible mechanisms leading to BBB disruption in MS. For explanation, please see the main text (modified from Minagar
and Alexander147).
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BBB in Parkinson’s disease
Using histologic markers of serum protein, iron and
erythrocyte extravasation, it has been shown signiﬁ-
cantly increased permeability of the BBB in part of
the caudate putamen of PD patients.149
It has been established that the process of reactive glio-
sis is a common feature of astrocytes during BBB disrup-
tion, which may have implications of astrocyte functions
in the protection of the BBB, and in the development of
PD.150 It seems that alterations in BBB permeability can
also be reﬂected by changes in CSF/blood albumin,
although changes in CSF turnover might also be respon-
sible for such ﬁndings. Signiﬁcant diﬀerences in albumin
CSF/serum ratios (AR), based on samples obtained from
non-demented subjects with idiopathic PD and age-
matched control subjects, were found between patients
with advanced disease, and both early-stage and unaf-
fected groups. Conversely, early-phase patients did not
diﬀer from healthy subjects. Additionally, dopaminergic
treatment seems to exert a possible eﬀect on AR values.
This indicates possible dysfunction of the BBB (and/or
blood-CSF-barrier) in PD progression.151
Tight junctions. In a intracerebral rotenone model of PD
in rats, using ﬂuorescein as tight junctional BBB per-
meability marker, no changes were detected.106
Active transporters
P-glycoprotein. Brain distribution studies of paradigm
compounds selected based upon their diﬀerential trans-
port across the BBB (l-3,4-dihydroxyphenylalanine,
carbamazepine, quinidine, lovastatin and simvastatin)
was studied in healthy and MPTP-treated macaques.
Only changes in brain distribution of Quinidine were
found, indicating changes in P-gp functionality.152
In contrast, studies performed by Hou et al.153 sug-
gest that P-gp inhibition increases BBB permeability to
N-[2-(4-hydroxy-phenyl)-ethyl]-2-(2,5-dimethoxy-
phenyl)-3-(3-methoxy-4-hydroxy-phenyl)-acrylamide
(FLZ), a novel synthetic squamosamide derivative and
potential anti-PD agent. But, no signiﬁcant diﬀerences
were observed in the brain distribution of FLZ between
normal and PD model rats, suggesting no signiﬁcant
change in P-gp in PD.153
Bartels et al.154,155 investigated in vivo BBB P-gp
function in patients with parkinsonian neurodegenera-
tive syndromes, using [11C]-verapamil PET in
PD patients. Advanced PD patients had increased
[11C]-verapamil uptake in frontal white matter regions
compared with controls; while de novo PD patients.
The authors concluded that lower [11C]-verapamil
uptake in midbrain and frontal regions of de novo
PD patients could indicate a regional up-regulation of
P-gp function.154
However, in a later study of this group, the
decreased BBB P-gp function in early stage PD patients
could not be conﬁrmed.155
LRP1. Alpha-synuclein (a-Syn), being one of the
dominant proteins found in Lewy Bodies in brains of
PD, has been found in body ﬂuids, including blood and
CSF, and is likely produced by both peripheral tissues
and the CNS. Radioactively labelled a-Syn has been
found to cross the BBB in both the brain-to-blood
and the blood-to-brain directions at rates consistent
with saturable mechanisms. LRP-1 (but not P-gp)
seems to be involved in a-Syn eﬄux.156,157
Large neutral amino acid transporter (LNAA). BBB
transport of L-DOPA transport in conjunction with
its intra-brain conversion was studied in both control
and diseased cerebral hemispheres in the unilateral rat
rotenone model of PD. PD-like pathology, indicated by
a huge reduction of tyrosine hydroxylase as well as by
substantially reduced levels and higher elimination
rates of DOPAC and HVA, does not result in changes
in BBB transport of L-DOPA.158
MMPs. Like for Alzheimers disease and multiple scler-
osis, MMPs seem to have implications in PD,86,87 and
are associated in neurodegeneration of dopaminergic
neurons.86
Altogether it can be concluded that there is much
controversy on the role of the BBB in PD.
BBB in pharmacoresistant epilepsy
Older studies already indicated that seizures induce
BBB transport changes.159,160 Focal epilepsies are
often associated with BBB leakage. For example,
BBB leakage to albumin-bound Evans blue has been
found in PTZ induced epilepsy, with the location and
pattern depending on the rat strain.161
When a normal brain develops epilepsy (epilepto-
genesis), immunoglobulin G (IgG) leakage across the
BBB and neuronal IgG uptake increase concomitantly
with the occurrence of seizures. IgG-positive neurons
show signs of neurodegeneration, such as shrinkage
and eosinophilia. This may suggest that IgG leakage
across the BBB is related to neuronal impairment and
may be a pathogenic mechanism in epileptogenesis and
chronic epilepsy.162,163 The information on pharma-
coresistant epilepsy associated changes in the BBB are
relatively sparse.
Tight junctions
Claudin-8. Selective downregulation of claudin-8 by
kindling epilepsy164 suggests that selective modulation
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of claudin expression in response to abnormal neuronal
synchronization may lead to BBB breakdown and brain
oedema.
Transport systems
Facilitative glucose transport. Facilitative glucose
transport in the brain is aﬀected in diﬀerent patho-
physiological conditions including epilepsy. It has
been shown that GLUT1 mediates BBB transport of
some neuroactive drugs, such as glycosylated neuropep-
tides, low molecular weight heparin and D-glucose
derivatives.118
P-glycoprotein. A role for ABC transporters in the
pathogenesis and treatment of pharmacoresisant
epilepsy has been proposed.165–167 A positive associ-
ation between the polymorphism in the MDR1 gene
encoding P-gp (/ABCB1) and pharmacoresistant epi-
lepsy has been reported in a subset of epilepsy
patients.168 However, the follow-up association genetics
studies did not support a major role for this poly-
morphism.169,170 Then, an increased expression of P-
gp at the BBB has been reported, which was determined
in epileptogenic brain tissue of patients with pharma-
coresistant epilepsy171 as well as in rodent models of
temporal lobe epilepsy, including the pilocarpine
model. Other studies point to a profound role of sei-
zure-induced neuronal cyclooxygenase-2 (COX-2)
expression in neuropathologies that accompany epilep-
togenesis172 and it is thought that epileptic seizures
drive expression of the BBB eﬄux transporter P-gp
via a glutamate/COX-2 mediated signalling pathway.
Discussion and outlook
In summary, this review highlights several important
key points of the disruption of BBB during the pro-
cess of aging. First, the main players of the barrier
formation at the blood-brain interface are introduced.
Second, the possible multifactorial nature of matur-
ation of BBB and NVU during embryonic develop-
ment and postnatal period is presented. Then the
changes in phenotypes and functionality in physio-
logical aging and the consequent neurological impair-
ment are summarized. Third, the review focuses on
the cellular and molecular events and associated cere-
brovascular factors contributing pathologically to dif-
ferent neurodegenerative disorders. Although the
timing of disease symptoms and progression is very
important in e.g. Alzheimer’s disease, often patients
present with signiﬁcant tau and Ab load by the time
the symptoms begin. Given the contributions of vas-
cular impairments at certain points during the disease
process, it is important to investigate the vascular
pathology and BBB permeability conditions before
the disease becomes too severe to reverse. Finally, it
is clear that the majority of dementia types involve
an underlying small-vessel disease or cerebrovascular/
BBB dysfunction at some points during disease pro-
gression. However, the causality dilemma still exists
in identifying the circular cause and consequences
between vascular dysfunction and the clinical signs
of diﬀerent dementias and age associated neurodegen-
erative processes, which is an important exploratory
topic of future research.
The recognition of the role of eﬄux and uptake
transporters in the pathology of Alzheimer’s and PDs
and many other CNS diseases might oﬀer the avenue
for new therapeutic intervention strategies for the
pharmacological and clinical drug research for the ther-
apy of currently untreatable chronic neurodegenerative
disorders.
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